clonidine has been researched along with Cognitive Dysfunction in 3 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clonidine has similar pharmacological properties and can be administered both parenterally and orally." | 3.11 | Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial. ( Busund, R; Haaverstad, R; Helbostad, JL; Landsverk, SA; Martinaityte, I; Neerland, BE; Norum, HM; Ræder, J; Selbaek, G; Simpson, MR; Skaar, E; Skjærvold, NK; Skovlund, E; Slooter, AJ; Svendsen, ØS; Tønnessen, T; Wahba, A; Wyller, TB; Zetterberg, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, YX | 1 |
| Wang, H | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 1 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 1 |
| Li, J | 1 |
| Zhang, HY | 1 |
| Mao, F | 1 |
| Neerland, BE | 1 |
| Busund, R | 1 |
| Haaverstad, R | 1 |
| Helbostad, JL | 1 |
| Landsverk, SA | 1 |
| Martinaityte, I | 1 |
| Norum, HM | 1 |
| Ræder, J | 1 |
| Selbaek, G | 1 |
| Simpson, MR | 1 |
| Skaar, E | 1 |
| Skjærvold, NK | 1 |
| Skovlund, E | 1 |
| Slooter, AJ | 1 |
| Svendsen, ØS | 1 |
| Tønnessen, T | 1 |
| Wahba, A | 1 |
| Zetterberg, H | 1 |
| Wyller, TB | 1 |
| Sun, M | 1 |
| Dong, Y | 1 |
| Li, M | 1 |
| Zhang, Y | 1 |
| Liang, F | 1 |
| Zhang, J | 1 |
| Soriano, SG | 1 |
| Xie, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alpha 2 Adrenergic Receptor Agonists for the Prevention of Delirium and Cognitive Decline After Open Heart Surgery (ALPHA2PREVENT): Randomised Controlled Trial.[NCT05029050] | Phase 4 | 900 participants (Anticipated) | Interventional | 2022-01-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for clonidine and Cognitive Dysfunction
| Article | Year |
|---|---|
Alpha-2-adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): protocol for a multicentre randomised controlled trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Cardiac Surgical Procedures; Clonidine; Cognitive Dysfun | 2022 |
2 other studies available for clonidine and Cognitive Dysfunction
| Article | Year |
|---|---|
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Dexmedetomidine and Clonidine Attenuate Sevoflurane-Induced Tau Phosphorylation and Cognitive Impairment in Young Mice via α-2 Adrenergic Receptor.
Topics: Adrenergic alpha-2 Receptor Agonists; Age Factors; Animals; Behavior, Animal; Clonidine; Cognition; | 2021 |